Scholars@Duke
Omobonike Oyindasola Oloruntoba

Omobonike Oyindasola Oloruntoba

Associate Professor of Medicine
Medicine, Gastroenterology
Manage Profile
Embed Profile Data

Selected Publications

More Than Meets the Eye?

Journal Article Clin Liver Dis (Hoboken) · October 2021 Content available: Author Audio Recording. ... Full text Link to item Cite

Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features.

Journal Article Eur Radiol · June 2021 OBJECTIVES: The LI-RADS M (LR-M) category describes hepatic lesions probably or definitely malignant, but not specific for hepatocellular carcinoma in at-risk patients. Differentiation among LR-M entities, particularly detecting cholangiocarcinoma-containi ... Full text Link to item Cite

Provider Attitudes and Practice Patterns for Direct-Acting Antiviral Therapy for Patients With Hepatocellular Carcinoma.

Journal Article Clin Gastroenterol Hepatol · April 2020 BACKGROUND & AIMS: Direct-acting antivirals (DAAs) are effective against hepatitis C virus and sustained virologic response is associated with reduced incidence of hepatocellular carcinoma (HCC). However, there is controversy over the use of DAAs in patien ... Full text Link to item Cite

Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection Is Associated With Increased Survival in Patients With a History of Hepatocellular Carcinoma.

Journal Article Gastroenterology · November 2019 BACKGROUND & AIMS: There is controversy regarding the benefits of direct-acting antiviral (DAA) therapy for hepatitis C virus (HCV) infection for patients with a history of hepatocellular carcinoma (HCC). We performed a multicenter cohort study to compare ... Full text Link to item Cite

Direct-Acting Antiviral Therapy Not Associated With Recurrence of Hepatocellular Carcinoma in a Multicenter North American Cohort Study.

Journal Article Gastroenterology · May 2019 BACKGROUND & AIMS: There is controversy over the effects of direct-acting antiviral (DAA) therapies for hepatitis C virus (HCV) infection on hepatocellular carcinoma (HCC) recurrence and tumor aggressiveness. We compared HCC recurrence patterns between DAA ... Full text Link to item Cite

"Too Female" for Liver Transplantation.

Journal Article Hepatology · December 2018 Full text Link to item Cite

Implementation of Pharmacogenetic Testing Within the Veterans Health Administration From 2011 to 2013.

Journal Article Mil Med · October 2016 We assessed implementation of precision medicine within the Veterans Health Administration. We analyzed the use of interleukin-28B (IL28B) pharmacogenetic test, which predicts interferon-α treatment response in patients with hepatitis C. Patients with favo ... Full text Link to item Cite

Role of patient factors, preferences, and distrust in health care and access to liver transplantation and organ donation.

Journal Article Liver Transpl · July 2016 Despite major improvements in access to liver transplantation (LT), disparities remain. Little is known about how distrust in medical care, patient preferences, and the origins shaping those preferences contribute to differences surrounding access. We perf ... Full text Open Access Link to item Cite

Integrating daclatasvir into hepatitis c therapy.

Journal Article Clin Liver Dis (Hoboken) · January 2016 Full text Link to item Cite

Gender-based disparities in access to and outcomes of liver transplantation.

Journal Article World J Hepatol · March 27, 2015 Despite comprising 35% of transplants, the number of female transplant recipients has continued to decline. Accordingly, there is a growing attention to the issue of access to and outcomes of liver transplantation in women. The purpose of this review is to ... Full text Link to item Cite